Sanofi to Acquire Kadmon for ~$1.9B

 Sanofi to Acquire Kadmon for ~$1.9B


  • Sanofi to acquire Kadmon for $9.50/share in cash making a total equity value of ~ $1.9B with a premium of 79% to a closing price of $5.30 on Sept 07, 2021. The acquisition is expected to be completed in Q4’21
  • The acquisition will bolster Sanofi’s transplant business with the addition of Kadmon’s Rezurock to treat patients with cGVHD. Sanofi’s transplant business already includes Thymoglobulin & Mozobil that are currently marketed in 65+ countries
  • Rezurock is the US FDA approved therapy to treat cGVHD in adult & pediatric patients aged ≥12yrs. who have failed 2 prior lines of systemic therapy & is currently being evaluated in P-II trial for dcSSc

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Medcity News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on

Related post